{"product_id":"global-gene-expression-analysis-market-2023-2030","title":"Global Gene Expression Analysis Market - 2023-2030","description":"\u003cp\u003eGlobal Gene Expression Analysis Market - 2023-2030\u003cbr\u003e\nGlobal Gene Expression Analysis Market reached US$ 4.5 billion in 2022 and is expected to reach US$ 8.6 billion by 2030 growing with a CAGR of 8.7% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eGene expression analysis is the study of how genes are transcribed to synthesize functional gene products, functional RNA species, or protein products. The study of gene regulation provides insights into normal cellular processes, such as differentiation and abnormal or pathological processes. Gene expression analysis provides valuable insight into the role of differential gene expression in normal biological and disease processes and in the identification and verification of biomarker signatures.\u003c\/p\u003e\n\n\u003cp\u003eReal-time PCR is the gold-standard technique for the verification of differential gene expression profiles. Transcriptome sequencing by next-generation sequencing enables the discovery of differentially expressed genes using a hypothesis-neutral approach. The advancements in gene expression profiling lead to better outcomes.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, the Laser capture microdissection (LCM) and microarray technology are providing the next revolution in the study of gene expression. Integration of artificial intelligence and machine learning give better outcomes as the logarithms are trained to provide accurate data during the entire procedure. These are the factors which are expected to drive the market in the forthcoming period.\u003c\/p\u003e\n\n\u003cp\u003eDynamics\u003c\/p\u003e\n\n\u003cp\u003eRising Technological Advancements\u003c\/p\u003e\n\n\u003cp\u003eThe growing technological advancements such as NGS and molecular services are boosting the demand for gene expression services. Additionally, the development of genomic databases, increased government funding for genomics, and personalized medicine growth will likely drive the market. Increasing government funding for genomics is one of the major factors leading to the development of the gene expression analysis market.\u003c\/p\u003e\n\n\u003cp\u003eIn March 2023, Illumina released its new Connected Insights, cloud-based software that provides tertiary analysis for clinical next-generation sequencing (NGS) data. Connected Insights is the next step in creating a fully integrated software ecosystem that scales with the pace of discovery across NGS applications.\u003c\/p\u003e\n\n\u003cp\u003eIntegration of artificial intelligence (AI)\u003c\/p\u003e\n\n\u003cp\u003eApplication of AI\/ML algorithms for statistical and predictive analyses using whole genome sequencing for gene variants, and RNA-seq and microarrays for gene expression is observed these days as the outcome is accurate and more reliable for profiling. In gene expression microarray data, machine learning-based feature selection approaches like gene selection approaches will help to select the required genes from the pool.\u003c\/p\u003e\n\n\u003cp\u003eOn June 1, 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, launched the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients. PrimateAI-3D addresses a critical challenge facing the successful implementation of personalized genomic medicine. It also greatly improved the accuracy of genetic risk prediction.\u003c\/p\u003e\n\n\u003cp\u003eHigh Costs of Gene Expression Profiling\u003c\/p\u003e\n\n\u003cp\u003eThe high cost associated with sequencing posed a significant challenge to market growth in the last decade. In 2003, the first human genome sequenced by the Human Genome Project required ~USD 2.7 billion in funding. However, several technological developments have taken place in the field of genomics, which were aimed at increasing the speed and reducing the expenses associated with sequencing.\u003c\/p\u003e\n\n\u003cp\u003eThe NHGRI (National Human Genome Research Institute, US) has tracked the sequencing costs at its various funded genome sequencing centers for many years and estimated the cost of genome sequencing in the years following the Human Genome Project. Based on this data, the NHGRI estimated that in 2006, it would have likely cost over USD 20–25 million to generate a finished human genome sequence, while by late 2015, the price to develop a high-quality whole human genome sequence draft had fallen below USD 1,500. The cost to generate a whole-exome sequence was generally below USD 1,000.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global gene expression analysis market is segmented based on product type, technique, application, end-user and region.\u003c\/p\u003e\n\n\u003cp\u003eThe RNA Sequencing Segment Accounted for Approximately 42.9% of the Market Share\u003c\/p\u003e\n\n\u003cp\u003eRNA Sequencing is expected to hold the largest market share as the technique uses next-generation sequencing (NGS), AI to reveal the presence and quantity of RNA in a biological sample. With the advent of machine learning and other technological advancements, gene expression analysis accuracy has increased.\u003c\/p\u003e\n\n\u003cp\u003eIn March 2023, Alithea Genomics, a Lausanne-based start-up that specializes in high-throughput RNA sequencing, secured a CHF 500,000 Tech Growth loan from the Foundation for Technological Innovation (FIT). RNA sequencing is a valuable tool in biomedical research, allowing scientists to examine gene expression, discover new biomarkers, and develop new drugs. Alithea Genomics aims to address this challenge with its proprietary technology, Bulk RNA Barcoding followed by sequencing (BRB-seq), which can prepare thousands of RNA samples for sequencing in a single tube, unlike standard RNA-seq sample preparation\u003c\/p\u003e\n\n\u003cp\u003eGeographical Analysis\u003c\/p\u003e\n\n\u003cp\u003eNorth America accounted for Approximately 39.2% of the Market Share in 2022\u003c\/p\u003e\n\n\u003cp\u003eNorth America is dominating the global gene expression analysis market, with the United States accounting as the major contributor to the market. The United States spends the most compared to other countries on genomics research, corresponding to 40% of worldwide public funding.\u003c\/p\u003e\n\n\u003cp\u003eCitizens and taxpayers of several countries have funded much of the research and have expectations about access to the resulting information and knowledge. While access to knowledge gained from all publicly funded research is desired, access is essential for fields that have a broad social impact and stimulate public dialogue. Innovate UK has up to £5 million to support capital investment in equipment that increases the UK’s capacity to produce and commercialize genomic analysis technologies.\u003c\/p\u003e\n\n\u003cp\u003eMost of the major key players are based in North America such as Illumina, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Luminex Corporation, etc. are contributing to making this region the largest shareholder in gene expression analysis market. For instance, in Jan 2022, Illumina Inc. announced a multi-year agreement with Nashville Biosciences LLC to increase medicines development via large-scale genomics and also the formation of clinical-genomic resource that is pre-eminent with the help of Illumina's next-generation sequencing (NGS)\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global gene expression analysis market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting healthcare innovations worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to industries.\u003c\/p\u003e\n\n\u003cp\u003eThe focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of genetic research and development activities. This has led to delays in the completion of trials and the availability of new diagnostic procedures and therapies, which has affected the market.\u003c\/p\u003e\n\n\u003cp\u003eBy Product Type\u003cbr\u003e\n• Instruments\u003cbr\u003e\nPCR (Polymerase Chain Reaction)\u003cbr\u003e\nNGS (Next Gen Sequencing)\u003cbr\u003e\nMicroarray\u003cbr\u003e\nOthers\u003cbr\u003e\n• Services\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Technique\u003cbr\u003e\n• RNA Expression\u003cbr\u003e\nPCR\u003cbr\u003e\nRNA Sequencing\u003cbr\u003e\nNorthern Blotting\u003cbr\u003e\nDNA Microarrays\u003cbr\u003e\nOthers\u003cbr\u003e\n• Promotor Analysis\u003cbr\u003e\nGel Shift Assays\u003cbr\u003e\nChromatin Immunoprecipitation\u003cbr\u003e\nIn Vitro transcription Run on Assays\u003cbr\u003e\nOthers\u003cbr\u003e\n• Protein Expression \u0026amp; Post Translational Modification Expression\u003cbr\u003e\nImmunoassays\u003cbr\u003e\nmass spectrometry\u003cbr\u003e\nWestern Blotting\u003cbr\u003e\n2D gel Electrophoresis\u003cbr\u003e\nOthers\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Application\u003cbr\u003e\n• Drug Discovery and Development\u003cbr\u003e\n• Clinical Diagnostics\u003cbr\u003e\n• Biotechnology and Microbiology\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy End User\u003cbr\u003e\n• Biotechnology \u0026amp; Pharmaceutical Companies\u003cbr\u003e\n• Diagnostic Laboratories\u003cbr\u003e\n• Academic Research Centers\u003cbr\u003e\n• Contract Research Organisation\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nU.K.\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n• In May 2023, 10x Genomics, Inc., a leader in single cell and spatial biology, announced today the commercial availability of a new Visium CytAssist Gene and Protein Expression product to expand the breadth of the Visium CytAssist spatial analysis capabilities. It enables researchers to simultaneously produce highly multiplexed protein and whole transcriptome RNA data mapped together from the same formalin-fixed, paraffin-embedded (FFPE) tissue section at high spatial resolution.\u003cbr\u003e\n• On June 1, 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, launched the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients. PrimateAI-3D addresses a critical challenge facing the successful implementation of personalized genomic medicine. It also greatly improved the accuracy of genetic risk prediction.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the gene expression analysis market include QIAGEN, Merck KGaA, Genscript Biotech Corporation, Bio-Rad Laboratories, Takara Bio Inc., Thermo Fisher Scientific, Inc., Promega Corporation, Agilent Technologies, Lonza Group Ltd., New England Biolabs Inc. among others.\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global gene expression analysis segmentation based on product type, technique, application, end user and region as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n• Excel data sheet with numerous data points of gene expression analysis market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global gene expression analysis market report would provide approximately 53 tables, 54 figures, and 195 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 195 Pages \/ MCW16232350","offer_id":47647494111538,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-gene-expression-analysis-market-2023-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}